Read more

June 15, 2020
1 min read
Save

Zimura continues to reduce geographic atrophy growth at 18 months

Zimura showed positive results at 18 months in a phase 3 clinical trial in patients with geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric bio.

The 18-month results of Zimura (avacincaptad pegol), a novel complement C5 inhibitor, support the positive 12-month results, in which Zimura met the specified primary endpoint with statistical significance, the release said.

In the Zimura 2 mg group, the reduction in the mean rate of geographic atrophy growth was 28.11% at 18 months compared with the sham control group (P = .0014). In the Zimura 4 mg group, the reduction was 29.97% compared with the sham control group (P = .0021).

The treatment began showing effectiveness as early as 6 months and continued to show an increase in absolute difference of mean change in geographic atrophy growth at each time point compared with the sham treatment.

“We are one step closer to potentially bringing a clinically meaningful therapy to patients with GA who currently do not have any FDA- or EMA-approved treatments available to them,” Kourous A. Rezaei, MD, chief medical officer of Iveric, said in the release. “We believe the robust 18-month efficacy data further validates the potential role of complement C5 inhibition in GA secondary to AMD and has the potential to differentiate Zimura from other product candidates in development.”

At 18 months, no Zimura-related adverse effects were reported, along with no cases of endophthalmitis and a lower rate of neovascularization than what is reported for C3 inhibition.

The company is planning to begin a second pivotal trial comparing the 2 mg dose with sham later this month, according to the release.